Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Annovis Bio Inc ANVS

Healthcare Biotechnology
Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced... see more

Recent & Breaking News (NYSE:ANVS)

Annovis Bio Highlights New Alzheimer's Data at the Alzheimer's Association International Conference® 2024

GlobeNewswire June 18, 2024

Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients

GlobeNewswire June 11, 2024

Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast

GlobeNewswire June 5, 2024

Annovis Announces New Publication in a Peer-Reviewed Journal

GlobeNewswire May 21, 2024

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

Business Wire May 17, 2024

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

Business Wire May 16, 2024

The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

Business Wire May 16, 2024

Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results

GlobeNewswire May 13, 2024

Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's Disease

GlobeNewswire May 9, 2024

Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders

GlobeNewswire May 6, 2024

Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer's Disease

GlobeNewswire April 29, 2024

Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire April 2, 2024

Annovis Announces Publication That Supports Understanding of Buntanetap's Mechanism of Action in Humans

GlobeNewswire April 1, 2024

Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease

GlobeNewswire March 20, 2024

Annovis Bio Announces Participation in Forum Discussion at AD/PD(TM) 2024

GlobeNewswire February 27, 2024

Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer's Disease

GlobeNewswire February 14, 2024

Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company's Portfolio

GlobeNewswire January 30, 2024

Annovis Bio Refines Timeline for Parkinson's Phase III Study Data Announcement

GlobeNewswire January 24, 2024

Annovis Bio to Participate in the 139th Yale CEO Summit

GlobeNewswire December 11, 2023

Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson's Disease

GlobeNewswire December 5, 2023